四環醫藥：中期報告2023.pdf

1、(incorporated in Bermuda with limited liability)（於百慕達註冊成立之有限公司）Stock Code 股份代號：0460Sihuan Pharmaceutical Holdings Group Ltd.四環醫藥控股集團有限公司2023 Interim Report 中期報告公司簡介CORPORATE PROFILEFounded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010,Sihuan Pharmaceutical H

2、oldings Group Ltd.(“Sihuan Pharmaceutical”or the“Company”,together with its subsidiaries,the“Group”)(Stock Code:00460.HK)is an international medical aesthetic and biopharmaceutical company led and driven by innovation,with an independent and leading research and development(“R&D”)technology platform

3、,a rich global product pipeline,strong product registration capability,a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system.Adhering to the overall strategic objective of“full promotion of a two-wheel drive strategy of its medical aesthetic

4、s and biopharmaceutical businesses”,Sihuan Pharmaceutical endeavours to build itself into a leading medical aesthetics and biopharmaceutical company in China.四環醫藥控股集團有限公司（四環醫藥 或 本公司，連同其附屬公司為本集團）（股份代號：00460.HK）創立於二零零一年，二零一零年於香港聯合交易所有限公司主板上市，是一家以創新為引領，堅持創新驅動，擁有獨立領先的自主研究與開發（研發）技術平台，具備豐富的全球化產品管線，強大的產品註冊

5、能力，高效率及低成本的全劑型生產平台和成熟卓越銷售體系的國際化醫美及生物製藥企業。四環醫藥一直秉承 堅持全速推進四環醫美及生物製藥雙輪驅動戰略 的整體戰略目標來打造中國領先的醫美及生物製藥企業。目錄CONTENTS2 公司資料 Corporate Information4 管理層討論及分析 Management Discussion and Analysis54 其他資料 Other Information70 獨立審閱報告 Independent Review Report72 中期簡明綜合損益及其他全面收益表 Interim Condensed Consolidated Statement

6、 of Profit or Loss and Other Comprehensive Income74 中期簡明綜合財務狀況表 Interim Condensed Consolidated Statement of Financial Position76 中期簡明綜合權益變動表 Interim Condensed Consolidated Statement of Changes in Equity78 中期簡明綜合現金流量表 Interim Condensed Consolidated Statement of Cash Flows80 中期簡明綜合財務資料附註 Notes to the